Aveanna Healthcare (NASDAQ:AVAH) Shares Gap Down Following Insider Selling

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) gapped down before the market opened on Monday after an insider sold shares in the company. The stock had previously closed at $8.08, but opened at $7.83. Aveanna Healthcare shares last traded at $8.0480, with a volume of 224,325 shares changing hands.

Specifically, CFO Matthew Buckhalter sold 18,340 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $7.85, for a total value of $143,969.00. Following the sale, the chief financial officer directly owned 436,980 shares of the company’s stock, valued at $3,430,293. The trade was a 4.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Matthew Buckhalter sold 17,289 shares of the business’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $8.18, for a total value of $141,424.02. Following the completion of the sale, the chief financial officer directly owned 455,320 shares in the company, valued at $3,724,517.60. This trade represents a 3.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In other news, CFO Matthew Buckhalter sold 17,448 shares of the stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $8.36, for a total value of $145,865.28. Following the sale, the chief financial officer directly owned 472,609 shares of the company’s stock, valued at approximately $3,951,011.24. This represents a 3.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Wall Street Analysts Forecast Growth

AVAH has been the topic of a number of analyst reports. JPMorgan Chase & Co. upgraded shares of Aveanna Healthcare from an “underweight” rating to a “neutral” rating and upped their price target for the stock from $6.00 to $10.00 in a research note on Thursday, September 18th. William Blair started coverage on shares of Aveanna Healthcare in a report on Monday, December 8th. They issued an “outperform” rating for the company. Royal Bank Of Canada upped their target price on shares of Aveanna Healthcare from $8.00 to $10.00 and gave the stock a “sector perform” rating in a research note on Friday, October 24th. UBS Group raised their price target on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the company a “neutral” rating in a research report on Friday, November 7th. Finally, Zacks Research lowered shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, October 20th. Five investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $10.69.

Aveanna Healthcare Price Performance

The stock has a market capitalization of $1.75 billion, a PE ratio of 23.31 and a beta of 2.06. The firm’s fifty day moving average price is $8.86 and its two-hundred day moving average price is $7.57. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 140.39.

Aveanna Healthcare (NASDAQ:AVAH) last posted its earnings results on Monday, May 22nd. The company reported $0.04 EPS for the quarter. The business had revenue of $450.53 million during the quarter. Aveanna Healthcare had a net margin of 3.29% and a negative return on equity of 143.55%. On average, equities analysts predict that Aveanna Healthcare Holdings Inc. will post -0.06 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AVAH. JPMorgan Chase & Co. grew its stake in shares of Aveanna Healthcare by 32.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 209,491 shares of the company’s stock valued at $1,858,000 after purchasing an additional 51,226 shares during the period. Caxton Associates LLP purchased a new position in shares of Aveanna Healthcare in the third quarter worth approximately $488,000. PharVision Advisers LLC grew its position in Aveanna Healthcare by 37.6% during the third quarter. PharVision Advisers LLC now owns 20,595 shares of the company’s stock valued at $183,000 after buying an additional 5,630 shares during the period. XTX Topco Ltd purchased a new stake in Aveanna Healthcare during the third quarter valued at approximately $531,000. Finally, Voleon Capital Management LP purchased a new stake in Aveanna Healthcare during the third quarter valued at approximately $2,949,000. Institutional investors own 87.96% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.